Related references
Note: Only part of the references are listed.NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages
Yuhua Shi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor
Yun Chen et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases
Xiangna Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
MCC950 directly targets the NLRP3 ATP- hydrolysis motif for inflammasome inhibition
Rebecca C. Coll et al.
NATURE CHEMICAL BIOLOGY (2019)
NLRP3 inhibitors stoke anti-inflammatory ambitions
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2019)
Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome
Humayun Sharif et al.
NATURE (2019)
REPLATINUM Phase III randomized study: RRx-001+platinum doublet versus platinum doublet in third-line small cell lung cancer
Bryan Oronsky et al.
FUTURE ONCOLOGY (2019)
One-Carbon Metabolism Supports S-Adenosylmethionine and Histone Methylation to Drive Inflammatory Macrophages
Weiwei Yu et al.
MOLECULAR CELL (2019)
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Karen V. Swanson et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Overview of the IL-1 family in innate inflammation and acquired immunity
Charles A. Dinarello
IMMUNOLOGICAL REVIEWS (2018)
Tranilast directly targets NLRP3 to treat inflammasome-driven diseases
Yi Huang et al.
EMBO MOLECULAR MEDICINE (2018)
OLT1177, a ß-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
Carlo Marchetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
Hongbin He et al.
NATURE COMMUNICATIONS (2018)
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials
Bryan Oronsky et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Hua Jiang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation
Tiantian Tang et al.
NATURE COMMUNICATIONS (2017)
NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component
Hexin Shi et al.
NATURE IMMUNOLOGY (2016)
K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria
Christina J. Gross et al.
IMMUNITY (2016)
NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
Yuan He et al.
NATURE (2016)
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial A TITE-CRM Phase I/II Clinical Trial
Michelle M. Kim et al.
TRANSLATIONAL ONCOLOGY (2016)
ASC filament formation serves as a signal amplification mechanism for inflammasomes
Mathias S. Dick et al.
NATURE COMMUNICATIONS (2016)
Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models
Michael J. D. Daniels et al.
NATURE COMMUNICATIONS (2016)
Inflammasomes: mechanism of assembly, regulation and signalling
Petr Broz et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Inflammasome-Independent Regulation of IL-1-Family Cytokines
Mihai G. Netea et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis
Roni Nowarski et al.
CELL (2015)
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Tony Reid et al.
LANCET ONCOLOGY (2015)
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Jianjin Shi et al.
NATURE (2015)
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Rebecca C. Coll et al.
NATURE MEDICINE (2015)
Inflammasomes: mechanism of action, role in disease, and therapeutics
Haitao Guo et al.
NATURE MEDICINE (2015)
Mitochondria: diversity in the regulation of the NLRP3 inflammasome
Prajwal Gurung et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization
Tamanna Haq et al.
NATURE COMMUNICATIONS (2015)
Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes
Alvin Lu et al.
CELL (2014)
Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome
Hao Xu et al.
NATURE (2014)
K+ Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter
Raul Munoz-Planillo et al.
IMMUNITY (2013)
TLR Agonists Stimulate Nlrp3-Dependent IL-1β Production Independently of the Purinergic P2X7 Receptor in Dendritic Cells and In Vivo
Yuan He et al.
JOURNAL OF IMMUNOLOGY (2013)
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice
Michael T. Heneka et al.
NATURE (2013)
Treating inflammation by blocking interleukin-1 in humans
Charles A. Dinarello et al.
SEMINARS IN IMMUNOLOGY (2013)
Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials
Shoucheng Ning et al.
CANCER RESEARCH (2012)
A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation?
Haitao Wen et al.
NATURE IMMUNOLOGY (2012)
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Charles A. Dinarello et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Development of a Safe and Efficient Two-Step Synthesis for Preparing 1-Bromoacetyl-3,3-dinitroazetidine, a Novel Clinical Anticancer Candidate
Nicholas A. Straessler et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2012)
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Beckley K. Davis et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis
Tomoaki Mori et al.
INTERNATIONAL IMMUNOLOGY (2011)
Caspase-1-Processed Cytokines IL-1β and IL-18 Promote IL-17 Production by γδ and CD4 T Cells That Mediate Autoimmunity
Stephen J. Lalor et al.
JOURNAL OF IMMUNOLOGY (2011)
A role for mitochondria in NLRP3 inflammasome activation
Rongbin Zhou et al.
NATURE (2011)
Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome
Christian Bauer et al.
GUT (2010)
NLRP3 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis by Mediating Th1 and Th17 Responses
Denis Gris et al.
JOURNAL OF IMMUNOLOGY (2010)
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell et al.
NATURE (2010)
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 beta in type 2 diabetes
Seth L. Masters et al.
NATURE IMMUNOLOGY (2010)
Target identification using drug affinity responsive target stability (DARTS)
Brett Lomenick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling
Joseph A. Duncan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis
Caroline Sutton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Gout-associated uric acid crystals activate the NALP3 inflammasome
F Martinon et al.
NATURE (2006)
Share Paper
